It has been quite the year in life sciences as we try to define a new normal following the pandemic. While funding struggled, breakthroughs abounded. In addition, the Food and Drug Administration continued its work on drug pricing and clinical trial diversity. We can’t capture it all in one article, but ... READ MORE >
5 things to know in life sciences: Week of Dec. 12, 2022
This week we look at the doctors creating a personalized medicine to help a specific patient who had exhausted all other options. We also highlight options for using data to support Medicare drug pricing negotiation, large scale DNA sequencing projects in infants, and efforts to use genome sequencing to ... READ MORE >
5 things to know in life sciences: Week of Dec. 5, 2022
This week we look at the Food and Drug Administration’s vaccine activity related to RSV and COVID-19, mRNA opportunities to treat cancer, diversity in clinical trials, and a large in-licensing deal highlighting the industry’s recent move away from traditional funding sources. Each week we highlight ... READ MORE >
5 things to know in life sciences: Week of Nov. 28, 2022
This week we look at mRNA technology that could be used in a universal flu vaccine, the rise in digital therapies despite a lack of insurance coverage, and another drug breaking the record for most expensive in the world. We also look at a new Centers for Disease Control and Prevention program to monitor ... READ MORE >
5 things to know in life sciences: Week of Nov. 14, 2022
This week we look at a program focused on identifying biases from artificial intelligence-powered diagnostics, a study exploring the possibility of dissolvable stents and staples, and an AI-powered solution targeted at physicians and caregivers. Finally, we review a Food and Drug Administration ... READ MORE >
5 things to know in life sciences: Week of Nov. 7
This week we’ve highlighted a medical battery that can be implemented without surgery and a new COVID-19 vaccine. We also look at enrollment challenges in clinical trials as well as a report on diversity in trial populations. Finally, we highlight a major acquisition in the medtech sector. Each week we ... READ MORE >
5 things to know in life sciences: Week of Oct. 31
This week we’ve highlighted the RSV vaccine race, J.P. Morgan’s private equity life sciences investment, a new product promoting decentralized oncology trials, the shocking expected cost of gene therapies, and Moderna’s revised earnings forecast amid falling COVID-19 cases. Each week we highlight five ... READ MORE >
5 things to know in life sciences: Week of Oct. 17
This week we’ve highlighted the White House’s strategy to address future pandemics, President Biden’s executive order on lowering prescription drug costs, the availability and reduced pricing of hearing aids, and the Food and Drug Administration’s updated authorization for Moderna and Pfizer-BioNTech ... READ MORE >
5 things to know in life sciences: Week of Oct. 10
This week, we look at collaboration arrangements in the areas of artificial intelligence and cancer treatment. We also highlight a retina scan that can predict heart disease and a digital treatment of lazy eye. Finally, we look at a pre-clinical biotech company that has raised $386 million in less than ... READ MORE >
5 things to know in life sciences: Week of Oct. 3
This week we look at how doctors are using virtual reality to help children manage their fear while in the hospital. We also highlight a new cloud analytics tool for wearables, drug pipeline planning and new research into the virus that causes monkeypox. Finally, we track the path from fossilized DNA to a ... READ MORE >